High incidence of Noonan syndrome features including short stature and pulmonic stenosis in patients carrying NF1 missense mutations affecting p.Arg1809: genotype-phenotype correlation by Rojnueangnit, Kitiwan et al.
Human Mutation
OFFICIAL JOURNAL
High Incidence of Noonan Syndrome Features Including
Short Stature and Pulmonic Stenosis in Patients carrying
NF1 Missense Mutations Affecting p.Arg1809:
Genotype-Phenotype Correlation
HGVê
HUMAN GENOME
VARIATION SOCIETY
www.hgvs.org
Kitiwan Rojnueangnit,1'2tJingXie,1+Alicia Games,1 Angela Sharp,1 Torn Gallens,1 Yunjia Chen,1 Ving Uu,1
Meagan Cochran,' Mary-Alice Abbott,3 Joan Atkin,4 Dusica Babovic-Vuksanovic,5 Christopher P. Barnett,6
Melissa Crenshaw,7 Dennis W. Bartholomew,4 Una Basel,8 Gary Bellus,9 Shay Ben-Shachar,10 Martin G. Bialer,11
David Bick,12 Bruce Blumberg,13 Fanny Cortes,'4 Karen L. David,15 Anne Destree,'6 Anna Duat-Rodriguez,17 Dawn Earl,18
Luis Escobar,'9 Marthanda Eswara,20 Begona Ezquieta,21 lan M. Frayling,22 Moshe Frydman,23 Kathy Gardner,24
Karen W. Gripp,25 Concepcion Hernandez-Chico,26 Kurt Heyrman,27 Jennifer tbrahim,28 Sandra Janssens,29 Beth A Keena,30
Isabel Llano-Rivas,31 Kathy Leppig,32 Marie McDonald,33 Vinod K. Misra,34 Jennifer Mulbury,35 Vinodh Narayanan,36
Naama Orenstein37 Patricia Galvin-Parton,38 Helio Pedro,39 Eniko K. Pivnick,40 Cynthia M. Powell,41 Linda Randolph,42
Salmo Raskin,43 Jordi Rosell,44 Karol Rubin,45 Margretta Seashore,46 Christian P. Schaaf,47 Angela Scheuerle,48
Meredith Schultz,49 Elizabeth Schorry,50 Rhonda Schnur,51 Elizabeth Siqveland,52 Amanda Tkachuk,9 James Tonsgard,53
Meena Upadhyaya,22 Ishwar C. Verma,54 Stephanie Wallace,18 Charles Williams,55 Elaine Zackai,30 Jonathan Zonana,56
Conxi Lazaro,57 Kathleen Claes,29 Bruce Korf,1 Yolanda Martin,26 Eric Legius,58 and Ludwine Messiaen1-
'Departmant of Genetics, Medical Genomics Laboratory, University ofAlabama t Birmingham, Birmingham, Alabama; 2Department of Pediatrics,
Faculty of Medicine,ThammasatUniversity, Bangkok, Thailand; 3Department of Pediatrics, Tufts University School of Medicine, Springfield.
Massachusetts;4Section fMolecular and Human Genetics, Nationwide Children's Hospital, Columbus, Ohio; 5Medical Genetics, Mayo Clinic
College ofMedicine, Hochestar, Minnasota; ePadiaïric and Reproductive Genetics, SA Clinical Genetics Service, Women's and Children's
Hospital/SA Pathology, North Adelaide, South Australia and Discipline of Pediatrics, University ofAdelaide, Adelaide, Australia; 7Department of
Clinical Genetics, All Children's Hospital, John Hopkins Medicine and Department of Pediatrics, John Hopkins University School of Medicine,
Baltimore, Maryland; SRaphael Recanati Genetics Institute, Beilinson Campus and Schneider Children's Medical Center of Israel/Felsenstein
Medical Research Center, Rabin Medical Center, Petach Tikva, Israël and Sackler Faculty of Medicine, Tel Aviv University, TelAviv, Israël;
9DepartmentofClimcalGenetics and Metabolism, Children's Hospital, UniversityofColorado, Denver-Aurora, Colorado; WThe Genetic Institute,
Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine,Tel-Aviv, Israël; "Department ofPediatrics,NorthShore LIJ HealthSystem,
Manhasset, New York; '2Section of Genetics, Department of Pediaü-ics, Medical College of Wisconsin, Milwaukse, Wisconsin; '3Kaiser
Permanente Oakland, Oakland, California; H Center for Rare Diseases, Clinica Las Condes, Santiago, Chile; 1SDepartmentofMedicine, Division of
Genetics, New Vork Methodist Hospital, Brooklyn, New Vork; wlnstitute of Pathology and Genetics IIPG), Gosselies, Belgium; "Department of
Neuropadiatrics, Hospita! Infantil Universitario Nino Jesüs, Madrid, Spain; "Department of Pediatrics, Division of Genetic Medicine, University of
Washington, and Seattle Children's Hospital, Seattle, Washington; '9Medical Genatics and Neurodevelopment Center, St Vincent Children's
Hospital, Indianapolis, lndiana;20SutterMemoriat Hospital, Sacramento, Califomia;2'DeparünentofBiochemistry, Hospital Universitario Gregorio
Maranón, Institute ofHeatth Research iliSGM), Madrid, Spain; 221nstitute ofMedical Genetics, University Hospital of Wales, Cardiff, UK; 23Chaim
Sheba Mediaal Center, Tal Hashomer, Israël; 24Department ofNeurology, Veterans Administration Hospital ofPittsburgh and Univarsity of
Pittsburgh, Pittsburgh, Pennsylvania; 2SDivision ofMedical Genetics, Al duPont Hospita! for Children, Wilmington, Delaware; 2eDepartment of
Genetics, Hospita! Universitario Ramón y Cajal, Institute ofHealth Research (IRYCIS). Center forBiomadicalHesearch-Network ofRare Diseases
{CIBERERI, Madrid, Spain;21 'Children's Haalth Center-Pediatrics, Appleton, Wisconsin;2aSt. Joseph's Children's Hospital, Paterson, New Jersey;
29 Center for Medical Genetics, Ghent ilniversity Hospital, Gent Belgium;30Division ofHuman Genetics, Children's Hospita! of Philadelphia,
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania;3]DepartmentofGenetics, Hospital UnivBrsitario Cruces, BioCruces
Health Research Institute, Biscay, Spain; 32Genetic Services, Group Health Cooperative and Department ofPathology, University of Washington,
Seattle, Washington; 33Department of Pediatrics, Division of Medical Genetics, Duke University Medical Centar, Dwham, North Carolina;
34DepartmentofPedi3tt'ics, Division ofGenetics andMetabolic Disorders, The Wayne State University School of Medicine, Detroit, Michigan;
3SDepartment of Pediatrics and Neurology, University ofRochester Medical center, Rochaster, Naw York; 3SDorrance Center for Rare Childhood
Disorders, Translational Ganomics Research Institute (TGen), Phoenix, Arizona; 37Genetics Unit Schneider Children's Medical Center of Israël,
Petach Tikva, Israël; 3SStony Brook Children's Stony Brook Medicine, Stony Brook, New York; 39Medical Genetics, Hackensack University
Medical Center, Hackensack, New Jersey; 4<>Department of Pediatrics, Division ofMedical Ganatics and Department of Ophthalmology University
of Tennessee Health Sclence Center and Le Bonhew Children's Hospita l, Memphis, Tennessee;4'DepartmentofPediatrics, University of North
Additional Supporting Information may be found intheonlineversionofthisarticle.
tThese authors contributed equallyto this work.
. Correspondence to: Ludwine Messiaen, Department of Genetics, Medical Genomics Laboratory, University ofAlabama t Birmingham, 720 20th Ave S, Birmingham, AL. Email:
lmessiaen@uabmc.edu
© 2015 TheAuthors. "JiümanMuterionpublishedbyWileyPeriodicals, Inc.
This is an open access arüde under the terms of the Creaüve Commons Attribution-NonCommerdaI-NoDerivatives License, which pennits use and distribution m any medium,
provided the origmal work is properly cited, the use is non-commercial nd no modifications or adaptations are made,
Carolina, Chapel Hill, North Carolina; 42Division ofMedical Genetics, Children's Hospital Los Angeles, Los Angeles, California; i3Group for
Advanced Molecular Investigation (NIMA), School of Heatth and Biosciences, Pontificia Universidade Catolica do Parana {PUCPRI, Curibita,
Brasil; 44Genetics Service, Hospital Son Espases, Palma de Mallorca, Spain; 4SUniversity ofMinnesota Children's Hospital, Minneapolis,
Minnesota;  Departmenï ofPediatrics and Genetics, Yale School ofMedicine, New Haven, Connecticut; "Department ofMolecular and Human
Genetics, Baylor College ofMedicine, Houston, Taxas; 4eDepartment of Pediatrics, University of Texas Southwestem Medical Center, Dallas,
Texas; 4SNationwide Children's Hospital, Columbus, Ohio; 50Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio; 51Division of
Benetics, Cooper Medical School of Rowan University, Camdan, New Jersey; s2Children'sHospitals and Clinics of Minnesota, Minneapolis,
Minnesota; 53Departments of Pediatrics and Neumlogy, University of Chicago/Pntzker School ofMedicine, Chicago, lllinois; 5fDepartment of
Genetic Mgdicine, Sri Ganga Ram Hospital, New Delhi, India; s5Department of Pediaü-ics, Division of Genetics and Melabolism, University of
Florida, Gainesville, Florida; se0epartments of Pediatrics and Molecular and Medical Genetics, Oregon Health and Science University, Portland,
Oregon;57MolecularDiagnostics Unit, Hereditary Cancer Program, Catalan Institute of Oncology flCO-IDIBELL), L'Hospitalet de Llobregat,
Barcelona, Spain; stDepartment of Human Genetics, KU Leuven, Leuven, Belgium
Communicated by David N. Cooper
Received 20 Mareh 2015; acceptedrevised manuscript 19 June 2015.
Published online 14 July 2015 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22832
ABSTRACT: Neurofibromatosis type l (NF1) is one of
the most frequent genetic disorders, affecting 1:3,000
worldwide. Identification of genotype-phenotype corre-
latlons is challenging because of the wide range clinical
variability, the progressive nature of the disorder, and
extreme diversity of the mutational spectrum. We re-
port 136 indlviduals with a distinct phenotype carrying
one of five different NF1 missense mutations affecting
p.Argl809. Patients presented with multiple café-au-lait
macules (CALM) with or without freckling and Lisch nod-
ules, but no extemally visible plexifomi neurofibromas or
clear cutaneous neurofibromas were found. About 25% of
the individuals had Noonan-like features. Pulmonic steno-
sis and short stature were significantly more prevalent
compared with classic cohorts (P < 0.0001). Develop-
mental delays and/or leaming disabilities were reported in
over 50% of patients. Melanocytes cultured from a CALM
in a segmental NFl-patient showed two different somatic
NF1 mutations, p.Argl809Cys and a multi-exon deletion,
providing enetic evidence that p.Argl809Cys is a loss-
of-function mutation in the melanocytes and causes a pig'
mentary phenotype. Constitutional missense mutations at
p.Argl809 affect 1.23% of unrelated NF1 probands in
the UAB cohort, therefore this specific NF1 genotype-
phenotype correlation will affect counseling and manage-
ment of a significant number of patients.
Hum Mutat 36:1052-1063, 2015. Published 2015 WUey Period-
icals, Inc.*
KEYWORDS:neurofibromatosis type l; NF1; p.Argl809;
phenotype-genotype correlations; Legius syndrome
Introduction
Neurofibromatosis type l (NF1; MIM #162200) is one of the
most frequent genetic disorders, characterized by café-au-lait mac-
ules (CALMs), skinfold freckling and Lisch nodules, neurofibromas,
optie pathway gliomas (OPG), and spedfic osseous lesions such as
sphenoid wing and tibial dysplasia. Approximately 50% ofpatients
present as "de novo" cases. NF1, located on chromosome 17qll.2,
has 57 constitutive and atleast 3 altemativelyspliced exons, spanning
282 kb of DNA. NF1 encodes neurofibromin, a GTPase activatmg
protein (GAP) down-regulatmg the biological acüvity of normal
Ras protems.
Only a few clinically significant genotype-phenotype corre-
lations are known. The first concerns a constitutional 1.4 Mb
microdeletion encompassing the NF1 gene. These padents present
with a more severe phenotype, mcluding mcreased neurofibroma
burden with an earlier age of onset, facial dysmorphism includ-
ing hypertelorism, coarse face, down-slanting palpebral fissures,
broad nasal bridge, ptosis, micrognathia, and developmental de-
lay/ intellectual disability or learning problems [Kayes et al., 1994;
Upadhyaya et al., 1998; Venturin et al., 2003; Descheemaeker et al.,
2004; MensüA et al., 2006; Mauüier et al., 2010; Pasmant et al.,
2010]. In addition, congenital cardiac defects such as pulmonic
stenosis (PS), atrial/ventricular septal defects, valve defects, hyper-
trophic cardiomyopathy, and patent ductus arteriosus [Venturm
et al., 2003; Nguyen et al., 2013]; connective tissue anomalies in-
cluding jomt laxity and hyperextensible skin; and skeletal anomalies
[Mensink et al., 2006; Mautner et al., 2010] are more frequently
found in these patients. These patients have an üicreased Ufe-time
risk for a malignant peripheral nerve sheath tumor (MPNST) [De
Raedt et al., 2003; Mensink et al., 2006]. Chüdhood overgrowth
and bone age acceleration occurs in patients with the common NF1
microdeletion. This contrasts with classical NF1 patients who have
short stature and whose prepubertal bone age is delayed by 1-2 years
[Carmietal.,1999].
A second genotype-phenotype correlation involves a specific one
amino acid NF1 deletion, p.Met992del, which is associated with
a müder NF1 phenotype consistmg mamly of pigmentary signs
(CAlMs and skmfold freckling) and a lack of externally visible
cutaneous or plexiform neurofibromas [Upadhyaya et al., 2007].
This mild phenotype of CALMs with or without frecHing but no
neurofibromas overiaps with and is clinically non-distinguishable
fromLegiussyndrome (LS), causedbymutationsmSPREDl [Brems
et al., 2007; Messiaen et al., 2009].
The lack ofdiscovery of more speci&c genotype-phenotype cor-
relations may be partly due to the methodological approach of
lumping mutations in gross categories, such as truncating, versus in
frame, spücing, and missense mutations [Sabbagh et al., 2013; van
Mmkelen et al., 2014]. However, high levds of ultra- and interfa-
miüal cUnical variabflity are observed m most NF1 famüies, even
though all afifected mdividuals carry identical NF1 mutations. The
confoundmg problem is that he phenotype is detennmed, besides
by the constitutional mutation, by the patient's age, the timmg ofsec-
ond hit mutations m different ceïïs and tissues, potential mosaicism
in founder patients and modifying and environmental factors.
We hypothesize that additional genotype-phenotype conelations
exist and likely can be identified through analysis of preferenriatly
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postpubertal patients carrymg the same non-truncating constitu-
tional mutation. Given the extreme diversity of the NF1 mutational
spectrum, with ~46% of parients carrying a private mutation
and only 29 different NF1 mutations present m >0.5% of aU
patients [Messiaen, 2008], identification funrelated, preferentiaüy
non-founder probands, and relatives over 8 years of age with an
identical mutation requires laige weU-characterized patiënt cohorts.
Multiple (>5) CALMs are usuaUy the first sign indicative ofNFl
and present shordy after birth. Up to 90% of the patients thereafter
develop skmfold fi-eckling before the age of S years, thereby fulfiU-
ing the clinical criteria ofNFl [Friedman et al., 1986aa]. Typically,
more signs and compUcations develop thereafter, but few mdica-
tors predict the severity of the disorder over time. TMs uncertainty
negatively impacts quality oflife [Vranceanu et al., 2013]. Recently
29 patients from 12 families carrying an NF1 missense mutation
at Argl809 were reported with a phenotype of multiple CALMs
and freckUng, without cutaneous or visible plexiform neurofibro-
mas, Lisch nodules, typical osseous lesions or symptomatic OPGs,
and with facial features uggestive of Noonan syndrome in 50%
[Pinna et al., 2015; Santoro et al., 2015], in line with our initial
findmgs [Rojnueangnit et al., 2013]. Here, we report a cohort of
136 patients from 98 unrelated famüies carrymg one of five dif-
ferent constitutional missense mutations affectmg NF1 codon 1809
in exon 29 [38]. Patients presented with multiple CALM, with or
without freckling and Lisch nodules, but externaUyvisible plexiform
neurofibromas (0/78 individuals £9 years; P< 0.05), symptomatic
optie pathway glioma (0/98 individuals > 5 years; P < 0.02) (Tables
l and 2) or clear cutaneous neurofibromas were not found. There
was, however, a high incidence of developmental delay/inteUectual
disabüity/learning disorder, PS, short stature, and Noonan syn-
drome features. This mutation was identified in 1.23% of unre-
lated probands carrying a constitutional NF1 mutation in the UAB
cohort (86/7,000). Missense mutations affectmg p.Argl809 are the
second most frequent mutation m the UAB cohort, second only to
the 1.4 Mb NF1 type l microdeleüon. This is the third specific NF1
genotype-phenotype correlation, which wül affect counseling and
management of these patients.
Materials and Methods
Patients and Phenotypic Characterization
Phenotypic data ofaU mdividuals carrymg an NF1 constituüonal
missense mutation affecting codon 1809, as provided by the refer-
ring physidans usmg a standardized phenotypic hecklist (Supp.
Fig. SI), weie reviewed. Initial results on 67 probands and 17 rel-
atives from UAB were reported at the 2013 American College of
Medical Genetics meetmg [Rojnueangnit et al., 2013]. This im-
tial study was expanded to include 31 additional probands <md
21 relfltives (from UAB and coUaborating centers) and refined by
requesting referrmg physidans to (i) verify whether the infomia-
tion in the origmally submitted checklist was accurate and (ü) pro-
vide an update on their patient(s) if additional information had
become avaüable. The phenotypic data documented m the stan-
dardized phenotypic heckUst mclude: age; sex; ethnicity; height;
head drcumference; NIH criteria mcluding CALMs, frecklmg, cu-
taneous, subcutaneous, plexiform and spmal neurofibromas, optie
gliomas, Lisch nodules, osseous lesion, and inheritance (familial,
sporadic); Noonan syndrome features induding short stature, ap-
parently low set ears, hypertelorism, midface hypoplasia, webbed
neck, and PS; cardiovascular defect (hypertension, pulmonic, aor-
tic or renal artery stenosis, Moyamoya, ASD, or VSD); develop-
ment (normal, abnormal, ADD, ADHD, leamüig disability, autism,
speech delay, pervasive developmental delay, IQ) and education;
presence/absence of ofher neoplasms. The UAB cohort comprises
111 individuals (86 probands and 25 relatives). In addidon, 25 indi-
viduals (12 probands and 13 relatives) from four other centers were
included: three Belgian families (six affected mdividuals) referred to
the Medical Genetics Laboratory at the University Ghent, Belgium
(UG), one Spanish family (three affected individuals) referred to
the Catalan Insdtute of Oncology, Barcelona, Spain (BARC), four
Spanish families (11 affected mdividuals) referred to the genedc de-
partment of the "Hospita! Universitario Ramon y Cajal, Madrid,
Spain (MADR) and four UK probands (three familial with genetic
and fuU clinical examination available on four individuals and one
proven sporadic individual) evaluated at the Institute of Medical
Genetics, University Hospital of Wales, UK (CARD) were mcluded.
The data for any given sign/symptom reflect he number of pa-
tients for whom we received information, that is, after exclusion of
those with entry "unknown" or "Not Specified." Screenmg for Lisch
nodules was not routinelyperformed in most patients. None of the
patients presented with ophthalmological problems mdicative of a
symptomatic OPG, but an MRI to exclude presence of an asymp-
tomatic OPG was not routmely performed, except when stated.
Simüarly, imaging or whole body MRI was not avaüable in patients
without signs or symptoms indicative ofintemal or spinal tumors.
A patiënt was classified as having short stature when height was
below or equal to the 3rd percentile (PC), usmg the World Health
Organization (WHO) growth curve for age less than 2 years, and
the Center for Disease Control (CDC) growth curve for age above
2 years m Caucasian and African-American ethnidty. For the Span-
ish individuals, Spaniards' growth charts were used as provided at
http://www.ebpediau-ica.com/endocrinoped/antropometria.php
As no specific growth curves are avaüable for the Hispanic and Asian
populations, but average height is lower than in the Caucasian or
African-American population [Hur et al., 2008; Chen and Chang,
2010; de Wüde et al., 2014], we conservatively excluded Hispanic or
Asian patients as having short or normal stature. We stül calculated
the PC values using the WHO or CDC growth curves and these
values are provided between square brackets in the Supp. Table SI.
Macrocephaly was defined as the head circumference above the
97th percentüe using the WHO curve for age up to 2 years old, and
the Gerhard NeUhaus' curve [Nellhaus, 1968] for age over 2 years
old, for all ethnic backgrounds.
A patiënt was classified as havmg "NF-Noonan" when at least wo
of the foUowing features were present: short stature, low set ears,
hypertelorism, idface hypoplasia, webbed neck, or PS.
Molecular Analyses
AU unrelated UAB, UG, BARC, and MADR probands had under-
gone comprehensive NFl-mutational analysis using an KNA-based
approach complemented by DNA-based osage analysis, as previ-
ously described [Ars et al., 2000; Messiaen et al., 2000; Messiaen and
Wünmer, 2005; Messiaen, 2008; Valere et al., 2011]. Melanocytes
from a GALM of patiënt UAB-RSeNF23 were cultured as previously
described [Maertens et al., 2007]. RNA and DNA were extracted
from cultured ceUs and subjected to comprehensive NF1 -mutational
analysis. Mutations in CARD individuals were identified usmg
DNA-based Sanger sequencmg ofallcodmg exons. NF1 mutations
are described foUowmg recommendations of the Human Genome
Variation Society using NM-000267.3 as the reference sequence.
Exon numbering uses the historica! nuinbering used by the NF1
consortium, foUowed by the NCBI numbermg in square brackets.
Low level mosaicism for the mutation affecüng codon 1809 in
the blood ofparents with ï-t CALMs (i.e" parent ofUAB-R3933,
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Tahle 1. Demographics and Clinical Features as Present According to Age Group (0-<8; 9-<18; >19 years) in Cohorts of tndividuals Carrying a Germline Missense Mutation p.Arg1809Cys,
p.Arg1809Leu, p-Arg1809Pro, p.Arg1809Ser, or p.Arg1809Gly
Mutation
Mutation positive
individuals
(proband:relatives)
Proband:Relative
Age groap
Age range/group
p.Aigl809Cys
(C.54250T;
33:6
0-^8
years
8 month-
8.5 years
107 (75:32)
31:5
9-SS18
years
9-18
years
11:21
£19
years
19-59
years
p.Argl809Leu
(c.5426G>T)
18(15:3)
10:1 3:0
0-:£8 9-^18
years years
émonth- 9-18
8 years years
2:2
£19
years
19-42
years
p.Argl809Pro
(c.5426G>C)
4 (4:0)
2:0
0-^8
years
1-4.5
years
2:0
9-^18
years
9-11
years
p.Argl809Ser
(C.54250A)
3 (3:0)
2:0
0-SS8
years
7
years
1:0
£19
years
19
years
p.Argl809Gly
(C.54250G)
4(1:3)
1:1
9-SS18
years
10
years
0:2
& 19
years
46-50
years
AllArgl809
47:7
0-^8
years
6 month-^8
years
136 (98:38)
37:6
9-SlS
years
9-18
years
14:25
>19
years
19-59
years
Total
136 (98:38)
98:38
Allages
6 months-
59 years
ï
£
s
s
a
Total (Male:fema]e)
Short stature1
Macrocephalyb
Fulfilling the NIH criteria if
die family history is taken
mto account
Fulfilling the NIH criteria if
soldy taküig the physical
signs mto account
>5 CALMs
Freckling
Lisch nodules
Cutaneous or subdennal
neurofibromas*
Plexiform neurofibromas
Optie pathway glioma by
MM
Pectus abnormallties
Bone abnormaUtiÉS(:
Noonan syndrome features'1
Pulmonic Stenosis/other
cardiac defect
Cognitive impairment/
leaming disabilities
39
(20:19)
5/21
(6/21)
4/27 .
(7/27)
22/39
37/39
15/38
3/27
0/39
(0%)
0/39
(0%)
0/13
2/39
5/39
11/38
(14/38)
5/35
(6/35)
21/37
36
(21:15)
11/25
(14/25)
10/27
(10/27)
27/36
36/36
25/34
3/25
2/36'
0/34
6/33
8/33
11/34
(14/34)
3/28
(4/28)
27/36
32
(13:19)
4/15
(4/15)
4/1(1
(5/10)
23/32
19/32
0/12
0/25
4/25
3/25
(8/25)
3/22
(6/22)
12/27
11
(8:3)
5/9
(5/9)
2/8
(3/8)
6/11
5/11
5/11
1/10
0/11
0/3
0/11
0/11
2/9
(5/9)
1/7
3
(1:2)
B/l
("/D
0/1
WD
3/3
3/3
3/3
0/3
0/3
0/3
0/3
0/2
(0/2)
0/3
4
(2:2)
0/3
(2/3)
0/2
(0/2)
3/4
2/4
2/4
0/4
0/4
0/4
0/4
1/4
(Irt)
0/2
2
(2:0)
0/1
(0/1)
0/1
(0/1)
0/2
0/2
0/2
0/1
0/2
1/2
0/2
(0/2)
0/1
2
(2:0)
1/1
(1/1)
0/1
(0/1)
2/2
2/2
2/2
1/2
0/2
0/1
0/1
1/1
0/2
(1/2)
0/1
1/2
2
(1:1)
0/1
(1/1)
0/1
(0/1)
2/2
2/2
2/2
2/2
0/2
0/2
0/2
1/2
1/2
1/1
(1/1)
1/1
l
(0:1)
1/1
(1/1)
NS
1/1
1/1
1/1
0/1
0/1
0/1
0/1
0/1
(1/1)
1/1
2
(1:1)
1/2
(1/2)
0/2
(0/2)
2/2
1/2
1/2
1/2
1/2
0/2
2
(1:1)
1/2
(1/2)
0/2
0/2
1/2
(2/2)
0/2
(1/2)
0/2
2/2
0/2
0/2
0/2
0/2
2/2
(2/2)
0/1
54
(31:23)
10/32
(12/32)
6/37
(10/37)
30/54
22/54
51/54
22/53
4/40
0/54
3/54
7/54
14/50
(20/50)
7/44
(8/44)
28/51
43
(25:18)
13/29
(16/29)
10/31
(10/31)
34/43
32/43
30/41
4/32
6/39
9/39
12/40
(17/40)
3/34
(5/34)
30/43
39
(16:23)
6/21
(8/21)
4/12
(5/12)
30/39
23/39
31/39
24/39
2/19
0/38
Wil
4/32
6/32
(12/32)
3/27
(6/27)
136
(72:64)
29/82
(36/82)
20/80
(25/80)
94/136
77/136
124/136
76/133
10/91
7/135
(7/82)*
0/132
9/125
20/125
32/122
(49/122)
13/105
(19/105)
71/127
*Presenceofcutaneousorsubdermalneurofibromas(NFs) questionable in all cases (7/135 patients of all ages or 7/82 patients of >:9years old), none biopsiedfor pathology: threepatientswifh l small subdermal lesion (NFvs. lipoma)» two patlents
with 2 "possible" small subdermal lesions (NF vs. lipoma), one patiënt with few (2-5) possible peripheral neurofibromas, one patiënt with nodules (8-10 mm) intemal part lower lip, tongue tip and basis by MRI, no hlstology.
"First value PC. S3; second value PC^5.
bpirst value PC>98; second value PC>90.
'AU bone abnormalities induded, that is, scoliosis (8x), pectus excavatum (7x), pectus carinatum (l x), long bone dysplasia (3 x), 2nd and 5th bflateral short oes, 4-5 toe syndactyly R foat, long 2nd and 3rd toes, dub foot, bone cysts, congenital
talus deformity and hip dysplasia» flat rlb cage. None of the patlents had a pseudarthrosis or sphenoid wing dysplasia.
dFirst value: patients with >2 Noonan signs (short stature, low set ears, hypertelorism, downslanting palpebral fissures, midface hypoplasia, webbed neck, pectus abnormality, or pulmonic stenosis); second value; patients with only l Noonan sign.
Patients with S: 2 Noonan signs had PTPN11 testing, all negative.
Table 2. Comparison of Clinical Features of the Arg1809 Cohort with the NF1 p,Met992del Cohort (Upadhyaya et al., 2007) and Previously
Reported Large-Scale NF1 Patiënt Cohorts
Number ofparients (%) P value (2-taüed Fisher's exact est)
NF1 feature p.Argl809a p.Met992delb Legiusc
Previous NF
cohortsd
p.Aigl809 versus
p.Met992del
p.Aigl809 versus
Legius
syndrome
p.Argl809 versus
previous NT
cohorts
>5 CALMs (and size
appropriate for age)
SkinfoldfrecUing(SF)e
>5 CALMs and SF, age
>9year
Lisch nodules
Cutaneous
neuiofibromas
Major external plexiforai
neurofibromase
Symptomatic optie
pathway glioma, age
>5yr
Noonan syndrome
features'
Pulmonic stenosis
Short staturek
Macrocephaly
Scoliosis1
Pectus abnormalities
Cognitive impairment/
leamtng disorders
124/136
(91.2)
54/80 (67.5)
52/80 (65)
10/91 (11.0);
10/119(8.4)
58/39 (12.8);
58/59 (8.5)
0/78 (0);
0/107 (0)
0/98 (0)h;
0/119(0)'
32/122 (26.2)
13/105 (12.4)
29/82 (35.4)
20/80 (25)
6/71 (8.5)
9/125 (7.2)
71/127"
46/47 (97.9)
30/47 (63.8)
22/34 (64.7)
3/30(10)
0/18 (0)
0/41 (0)
0/46 (0)
4(aUfroml
family)
4/47 (8.5)
5/47 (10.6)
4/45 (8.9)
2/20 (10)
7/45 (15.6)
8/47(17)
110/142(77.5)
42/89 (47.2)
35/92 (38)
O (n unknown)
0/68 (0)
0/95 (0)
0/118 (0)
19 reported
3 reported
10/85 (11.8)
25/111(22.5)
5 reported
15 reported
15/53 (karnmg
disabilities); 12/56
(psychomotor
developmental
delays); 11/52
(A(D)HD, autisdc
behaviour)"
1210/1297
(93.3)"-"
661/960
(68.9)°."
estimated at 95%
(95)
82/88 (93.2) A
99/99(100)*
7/115 (6.1) A
66/1383
(4.8)A,E, G,HJ
12/94 (12.8)
25/2322 (1.1) F
109/684
(l 5.9) A-B
239/704
(33.9) A-B
11/96
(H.5)A
36/127
(28.3) D
190/424
(44.8) A-E
0.0018 /
0.0086 /
0.0005 ^
0.0019 /
0.0335 /
0.0004 /
<0.0001 \
<0.0001
(<0.0001) \
<0.0001
(<0.0001)\
0.0429
(0.0146) \
0.0193
(0.0081) \
<0.0001 /
<0.0001 /
0.0467 \
<0.0001 \
.Tirst value are data fi-om dus study; second values are the data combined from this and previous studies (Ekvall et al., 2014; Nyström et al., 2009, Pinna et al., 2015; Santoro et al.,
2015); between round brackets: percentages.
bUpadhyayaetiil.(2007).
'Data compfled from Brems et al. (2007) (exdudmg UAB31,43,48,88, as these are iaduded in Messiaen et al. (2009)) (Demyer et al., 2011; Messiaen et al., 2009; Pasmant et al.,
2009; Spurlock et al.» 2009). For some features, total number of cases assessed for a given feature is unknown; only the number ofobservations is kaown and is stated here as
summarized by Brems et al. (2012).
dPrevious NT1 cohorts used for comparison: A: Huson et al. (1988); B: Khosrotehrani et al. (2005); C: Huson et al. (1989aa, Huson et al., 1989b); D: Cnossen et al. (1998); E:
McGaughran et al. (1999); F: Lm et al. (2000); G: Listemick et al. (1994); H; Singhal et al. (2002); I; Blazo et al. (2004).
eln patients >9 years in this study and > 10 years in ofher studies.
'bi patients S: 19 years in this study and £20 years m other studies.
SFlve individuals with few (1-6) small, subdermal possible neurofibromas," none were biopsied and therefore none have been histologically confirmed» therefore this is a very
conservatïve estimate.
Including 31 aged ï. 5 years who had an MRI and no asymptomatic OG present.
'Including 34 aged S5 years who had an MRI and no asymptomatic OG present.
]A patiënt was classified as having "Noonan-syndrome features" when at least 2of the following features were present: short stature, low set ears» hypertelorism, idface hypoplasia»
webbed neck, or pulmonic stenosis.
kShort stature defined as £PC3 in theArgl809 and Met992del cohort, in Huson et al. (1988), but as <PC5 m the Legius cohort.
In patients Ï. 9 years m this and previous tudies.
"Thiee indiriduals with said normal development and ADD (2) and ADHD (l) were counted as nomial but mduded toward the total number of cases in the denominator.
°Data as summarized in Brems et al. (2007).
UAB-R1593, UAB-R9044, UAB-R6935, and UAB-R3885) was in-
vestigated usmg High Resolution Melting Curve analysis, as
described [Vossen et al., 2009]. Genomic DNA was diluted to a
concentration of 15 ng//zl. A DNA sample from a non-founder m-
dividual carrymg the constitutional mutation c.5425C>T (present
in all cells, 50% of all alleles) was seriaüy diluted with wild-
type control DNA to generale a caübration panel with DNA con-
taining the mutation in 50%, 25%, 12.5%, 6.25%, 3.13%, and
1.56% of the alleles. AU samples were amplified in duplicate using
Lightscanner Master Mk (BioFire Defense) and the PCR products
were subsequendy analyzed by the LightScaimer® System (BioFire
Defense).
PTPN11 mutation analysis was performed in probands and rel-
atives with "NF-Noonan" phenotype by Sanger sequencing of all
coding exons and 20 nucleotides of the flaakmg introns (primer
sequences available upon request).
In Silico Prediction on the Mutations and their Effects on
3D Structure
The foUowing in süico prediction software programs
were used to assist with mterpretation of pathogenicity;
SIFT (sift.jcvi.org), PolyPhen (genetics.bwh.harvard.edu/pph2),
MutationTaster (http://www.mutationtaster.org), MutPred SpUce
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prediction (mutdb.org/mutpredspüce), and Grantham DiÉference
as embedded in Alamut visual v2.7.1.(http://www.interactive-
biosoftware.com) and CADD (cadd.gs.washington.edu). Presence
or absence of the variants against large control populations was
checked; lOOOGenomes (http://www.l000genomes.org),the Exome
Variant Server (http://evs.gs.washmgton.edu/EVS), and the Exome
Aggregation Consortium (http://exac.broadinstitute.org).
Evolutionary conservation for human neurofibromin
NP-000258.1 residues 1730-1815 was evaluated using ClustalW2
(http://www.ebi.ac.uk/Tools/msa/clustalw2). The structures of
human NF1 p.Argl809 mutations (Argl809Cys, Argl809Leu,
Aigl809Pro, Argl809Gly> Aigl809Ser, and Argl809His) were
predicted through the Analysis function ofUCSF Chimera (version
1.10.1), based on the crystal structure of human NF1 (RefSeq
NP.000258.1: PDB-accession code 2D4Q, residues 1560-1816 and
2E2X, residues 1567-1816).
This study was approved by the Institutional Review Boards of aU
participaring institutions offèring climcal genetic testing.
Results
The study mcludes 98 probands and 38 relatives carrymg a con-
stitutional missense mutation affectmg codon Argl809, and one
patiënt with segmental presentation mwhom we identified the mis-
sense p.Aigl809Cys in melanocytes cultured from a CALM, but not
in the blood.
Germline missense mutarions affectülg codonArgl 809 were iden-
tified in 86/7,000 unrelated NFl-positive probands through clinical
testing in the UAB Medical Genomics Laboratory (July 2003 to July
2014). Therefore, the frequency ofmissense mutations affecting this
codon is ~ 1.23% in individuals ubmitted for clmical testmg with
a positive genedc testmg result. This is the codon most frequenüy
mutated in NF1 in our cohort.
Characteristics and Location of the Mutations
Amongst 98 unrelated probands carrying mutations affecüng
codon 1809, five different missense mutations were observed:
p.ATgl809Cys(75/98),p.Argl809Leu(15/98),pArgl809Pro(4/98),
p.Argl809Ser (3/98), and p.Argl809Gly (1/98) and their character-
istics are summarized m Supp. Table S2. None of these variants
have been found in the lOOOGenomes, Exome Variant Server or
the ExAC control populations (61,486 unrelated individuals). We
never observed these missenses in a patiënt carrying a different
clear-cut pathogenic NF1 mutation (out of 7,000 NFl-mutation
positive probands), although a mother and daughter (famüy UAB-
R5153) carried a complex allele p.[Argl809Cys;Leul789Val], with
p.Leul789Val never observed or reported before and classified as a
variant ofunknown significance. Arginine at position 1809 is evolu-
tionarily conserved up to Drosophila melanogaster and yeast IRA2,
whereas the very sunflarbasic amino acid, Lysine, is found at that po-
sition in IRA1 (Supp. Fig. S2). AU in silico prediction programs clas-
sify these variants as deleterious (SIFT), disease-causing (Mutation-
Taster), or probably damagmg (PolyPhen). Combined Annotation
Dependent Depletion (CADD) vl.O dassified all missenses as being
more Ukely pathogenic (PHRED scores ranging from 21.9 to 34).
In addition, MutPred prediction software predicted p.Ai^l809Leu
to be a splice affectmg variant (score 0.69), whereas the other mu-
tations were predicted to be Splice Neutral Variants. KNA-based
sequencing showed that p.Argl809Leu and p.Argl809Pro (but not
p.Argl809Cys,p.Argl809Ser,orp,Argl809Gly)leadtoout-of-frame
skipping of exon 29 [38] and exon 29 + 30 [38 + 39] m a mmor
fraction of the ttanscripts. The missense mutations were proven to
segregate with the phenotype in 29 famiüal cases and to be de
novo in 21 sporadic probands. Taken together, these variants can all
confidendy be dassified as pathogenic according to cun-ent recom-
mendations [Richards et al., 2015].
Theoretically, substitution of a single nucleotide of the Argl809
codon CGC can result in six different missense variants: c.5425C>T,
p.Argl809Cys (codon TCC); c.5426G>C, p.Argl809Pro (codon
CCC); c.5426G>T, p.Argl809Leu (codon CTC); c.5425C>G,
p.Argl809Gly (codon GGC); c.5425C>A, p.Argl809Ser (codon
AGC) and c.5426G>A, p.Argl809His (codon CAC). As C>T and
G>A transitions are the most frequenüy observed mutations at
CpG dinucleotides, due to spontaneous deamination after cytosme-
methylation, we expected finding p.Argl809Cys and p.Argl809His
with equal frequency. However, p.Argl809His was not found
as a constitutional mutation in mutation-positive dinical sam-
ples submitted at UAB for NF1 testmg (0/7,000 vs. 67/7,000 for
p.Argl809Cys; P < 0.0001), whereas both are absent in the ExAC
control cohort (61,486 mdividuals). Aigl809 resides within the C-
terminal a-helix of the Pleckstrin Homology (PH) domain ofneu-
rofibromin,encompassing the aminoacids 1,713 to 1,816 (Supp.Fig.
S2). The function of this a-heUx within the domain is unknown,
but might be important for protein-protem interactions given its lo-
cation at the surface of the domain. 3D-modeling mdicates that all
Argl 809 missense mutations, mduding p.Argl809His, are predicted
to lose a hydrogen bond with Serl738 (Supp. Fig. S3). To fürther
investigate the discrepancy in prevalence of p.Argl809Cys versus
p.Argl809His, we verified whether partners were present within
suitable distance trom p.Argl809Cys to form disulfide bridges, but
none were found (Supp. Fig. S4).
Phenotypic Description of the Patiënt Cohort
The NF1 clinical features of 136 mdividuals with a constitutional
missense mutation affecting Argl809 and the pedigrees of famüial
cases are summarized in Table l, Table 2, Supp. Table SI, Supp. Ta-
ble S3, Supp. Figure S5, and Supp. Figure S6. Forty of 98 probands
were famüial cases, 21/98 were proven to have a de novo mutation
(with no formal patemity/maternity identity testing performed),
16/98 were reported as sporadic cases but one or both parents were
unavaüable for testing, and foi 21/98 cases famüy history was un-
known, includmg two adopted probands.
A 22-year old woman with segmental NF1, UAB-RSeNF23, (>6
CALMs and axillary fi-eckling all restricted to the left side of the
body, Lisch nodules m left eye, no learnmg disabilities, no OPG,
no PNF or cutaneous neurofibromas, no scoüosis or skeletal dys-
plasia) had no mutations identified in the blood, but two differ-
ent somatic NF1 mutations in the melanocytes cultured from a
CALM: c.5425C>T (p.Argl809Cys) and an in-frame deletion of 228
residues, c.(63^05)-(888-958)del (p.Arg69Jys296del).
Age of the individuals ranged firom 6 months to 59 yeais, with
54/136 mdividuals younger than 9 years, 43/136 between 9and 18
years, and 39/136 over 19 (10/39 between 19 and 26 years, 8/39
between 27 and 35 years, 16/39 between 36 and 50 years and 5/39
older than 50 years). Seventy-two were male, 64 were female.
Ninety-four out of 136 mdrviduals fiilfiüed NIH cUnical crite-
ria, but only 77/136 fulfiüed NIH criteria if family histoiy was ex-
cluded as a criterion. Fifty-two f 80 (65%) mdividuals >9 years
had >5CALMs and skmfold freckling (Tables l and 2). Three adults
(fanulial cases: UAB-R008-I1, UAB-R5863-I1, UAB-R6673-I1) had
only 1-2 CAIMs (with ü-regular margins) without other extemal
signs. Lisch nodules were rarely present (6/51 mdrviduals Ï. 9 years;
10/91 aU ages). A symptomatic OPG was absent m all 98 mdividuals
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>5 years. Moreover, an asymptomatic optie glioma was excluded
by MRI imaging in 39 individuals, including 32/39 S: 5 years. Exter-
naUy visible plexiform neurofibroma or symptomatic spinal neu-
rofibromas were not found in the 136 mdividuals in this cohort.
Furthermore, no spmal neurofibromas were found by MRI in six
asymptomatic mdividuals.
Cutaneous neurofibromas often first appear around the time of
puberty and mcrease m size and number with age. None of the indi-
viduals in this cohort had overt cutaneous neurofibromas, including
39 individuals > 19 years old (and 21/39 >35 years). In five patients
S 19 years (UAB-R744, 33y; UAB-R7641-I2, 47y; UAB-R0143-I1,
55y; UAB-R4174-I1, 40y; UAB-R4835, 28y; Supp. Tables SI and
S3), 1-2 small esions called possibly subdennal/peripheral neurofi-
bromas by the referrmg physidans were reported; none had been
histopathologicaüy confirmed. hl one patiënt (UAB-R3412, 15y),
multiple intramucosal oral nodules, suspected to be neurofibromas,
were identified by MRI, but no histologywas available.
Scoliosis was found m 6/71 patients older than 9 years. In 3/125
individuals, a long bone dysplasia was present, but pseudarthrosis
or sphenoid wing dysplasia was not seen. Pecms anomalies (pec-
tus carinatum or excavatum, flat rib cage) were reported in 9/125;
macrocephaly (PC >. 98) was present in 20/80.
Noonan syndrome features were present in 32/122 individuals.
No PTPN11 mutation was found in those available for testmg (0/22).
PS was present in 13/105 and short stature (PC < 3) in 29/82. Seven
individuals had a phenotype previously referred to as "Watson syn-
drome," given the combinaüon of multiple CALMs, PS and learn-
mg disabilities and/or intelligence at the lower end (UAB-R9216,
UG-575, UAB-R8141, UAB-R9851, UAB-R7626, UAB-R2635, and
UAB-R7961). Out of 136 individuals with constitutional missense
mutations at p.Argl 809, no developmental data were provided for 9;
53 were stated as having normal development; hree as having nor-
mal development but ADD was reported in two and ADHD m the
one. The remaining 71 individuals were reported to have abnormal
development presenting with one or a combination of the foUow-
ing forms ofcognitive impairment or learning dif&culties: leammg
disabilities (n = 62), developmental delays (n = 3), ADHD (n =13),
Aspergersyndrome(>t= l),pronundationproblems(n=l),speech
delay (n = 12), language delay (n = l), nasal speech and speech
apraxia (n = l), dyspraxia (n = l), dyslexia (n = l), motor delay
(n = 3) (Supp. Table SI and Table l). Seven patients had significant
leammg dif&culties and inteUectual disabüity, includmg four with a
Fuü Scale Intemgence Quoüent (FSIQ) between 58 and 75.
A venous malformation (multiple subcutaneous heman-
giomas/lymphangiomas, six nevi flammei, mildly bluish discol-
oration) and a Becker nevus were found m a child and mother
respectively (family UAB-R9813). A likely regressed hemangioma
(UAB-R0844), anevus anemicus (MADR-690), multiple cherry an-
giomas (UAB-R9266-I1), hemangiomas on left upper chest (UAB-
R3154-I1), and lumbar hemangioma plus involuted cutaneous he-
mangioma (UAB-R2135) were each found in a single patiënt.
One or mxildple Upomas were reported m three patients. A 24-
year-old woman had a diagnosis of breast cancer, a 50-year-old
woman had a breast fibroadenoma, and an 8-year-old boy had a
Ewing Sarcoma. No foUow-up information on these patients was
avaüable.
An Amold Chiari I malformation was present in three patients
(UAB-R0143-I1, UAB-R5913-II1, and MADR-694-II2). One pa-
tient (UAB-R4517) had abnormal morphologic appearance with
decreased transverse dimensions of the superior frontal lobes büat-
erally and an. unusual sulcation pattern in the superior right frontal
lobe, possibly mdicating a multifocal cortical dysplasia. Four pa-
tients had a brain lesion: a stable brain mass of unknown type
(UAB-R9216-I2), gUal nodules by MRI (UAB-R3133), astable dor-
sal medullar lesion suspicious for glioma (UAB-R5625) and a right
thalamic glioma, histologicaUy confirmed as being an astrocytoma
at age 17 years (UAB-R3773) and treated with stereotactic radio-
surgeiy and chemotherapy due to changes perceived on imaging.
The tumor has been stable post treatment. No material was avail-
able to investigate by genetic analyses whether the astrocytoma was
NFl-associated or coinddental.
There is no indicaüon that the severity of the pheno-
type differs amongst he five observed missense mutations, al-
though numbers are small for p.Argl809Gly, p.Argl809Pro, and
p.Argl809Ser.
Comparison of Clinical Features in Patients Carrying
Missense Mutations Affecting Codon 1809 with Patients
Carrying The NF1 P.Met992del Mutation, Patients With LS
and Patientswith "Classic NF1"
Comparison of clinical features of the p.Argl809 cohort with
mdividuals carrying the NF1 mutation p.Met992del [Upadhyaya
et al., 2007], LS [Brems et al., 2012, and references therein and
patients with "classic NF1" as previously reported in large scale
NF1 patiënt cohorts [Huson et al., 1988; Huson et al., 1989a;
Tonsgard et al" 1998; McGaughian et al., 1999; Lm et al., 2000;
Khosrotehrani et al., 2005] is summaiized in Table 2, with sta-
tistical significance calculated usmg two-tailed Fisher's exact test
(http://graphpad.com/quickcalcs/contingencyl/).
Compared to large cohorts of classic NF1 patients [Huson et al.,
1988; Huson et al., 1989aa; Listernick et al., 1994; Cnossen et al.,
1998; McGaughran et al., 1999; Lm et al., 2000; Singhal et al., 2002;
Blazo et al., 2004; Khosrotehrani et al., 2005], individuals with a
missense mutation at p.Argl809 have statistically significandy less
cutaneous and externally visible plexiform neurofibromas, ymp-
tomatic optie gliomas and pectus abnormalities. Fewer patients have
Lisch nodules. Importantly, no individual described m this and pre-
vious cohorts [Nyström et al., 2009; EkvaU et al., 2014; Pinna et al.,
2015] showed visible plexifonn neurofibromas (0/107 mdividuals
2:9 years) or symptomaüc optie gliomas (0/119 mdividuals >.5
years).
Compared with classic NF1 cohorts, individuals with a p.Argl809
missense mutation had significanüy increased frequency of PS
(P < 0.0001) and short stature (P < 0.0001). Short stature was also
significandy more frequent compared with individuak with NF1
p.Met992del or LS (all P values <0.002).
Phenotype in mdividuals carrying a p.Argl809 missense mu-
tation is smular to that of mdividuals with the NF1 p.Met992del
mutation [Upadhyaya et al., 2007], except for short stature being
more prevalent m the p.Argl809-positive mdividuals. In addiüon,
learning disabilities were more frequentiyreported m the p.Argl 809-
positive cohort.
95% ofmdividuals with classic NF1 fülfiU £2 of the NIH physical
criteria (i.e., not taking famüy history into account) by >9 years of
age accordmg to De BeUa, National Neurofibromatosis Foundation
International Database [Friedman et al., 1986a]. In contrast, mdi-
viduals with mutation at p.Argl809, p.Met992del or with LS less
likely fülfiU these criteria t £9 years of age (all P < 0.0001). Fur-
thermore, mdividuals with a mutation at pArgl809 or p.Met992del
dififer significandy fi-om mdividuals with LS, with mdividuals with
LS being the least likely to fülfill NIH criteria by age 9 years. Lisch
nodules were found m patients with a pArgl 809 mutation, although
rarely (10/91), but have never been reported in LS.
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Unusual Families within this Cohort
In 5/21 probands, with proven de novo mutation, one (UAB-
R9044, UAB-R3885, andUAB-R6935) orbothparents (UAB-R3933
and UAB-R1583) had 1-4 CALMs. Probands of these famüies in-
variablyhad >5 CALMs. p.Argl809 was not detected in the parental
blood samples by Sanger sequencing or by High Resolution Melt-
ing Curve Analysis (HRMCA), which would detect the mutation
if present at £3% minor allele frequency (data not shown). This
does, however, not completely exclude parental mosaicism for the
mutation.
Tumor-related phenotypes were strikingly discordant m affected
mdividuals within two families (Supp. Fig. S6). Comprehensive NF1
genetic testing showed two different mutations egregatmg within
these two families. In Family UG-575, the 7-yeai-old proband cairy-
ing the missense mutation p.Argl809Ser had multiple CALMs and
skmfold freckUng, Noonan phenotype with PS and severe learmng
disabüities with FSIQ of 58. Her father with >6 CALMs, >100 cuta-
neous neurofibromas, a large previously resected plexiform neurofi-
broma in the left leg and enlarged lumbar and sacral nerve roots by
MRI did not carry the mutation p.Argl809Ser (de novo in UG-575,
with biological relationship ofboth parents proven by identity test-
ing). Further comprehensive NF1 mutation analysis m him showed
a splice mutation, c. 6365-2A>G, resulting in out-of-frame skipping
ofexon 34 [43], and absent in his daughter.
In family UAB-R7916, the 41-year-old p.Argl809Cys-positive
proband had >8 CALMs, skinfold freckling, and PS. Four first-
degree p.Argl809Cys-negative relatives had 1-3 pigmentary lesions
(CALMs or hypopigmentation rfreckle). A 2-year-old niece of the
proband with >6 CALM, skinfold freckling and an intemal plexi-
form neurofibroma did not carry the mutation p.Argl809Cys, but
a de novo nonsense mutation c.539T>G, p.LeulSO*. Therefore, ifa
substantial deviation from the here described phenotype is found in
an mferred (i.e., a relative ofan mdividual with a proven p.Argl809
missense mutation) as well as m a proven p.Argl809 missense mu-
tation carrier, fürther genetic investigations should be pursued.
Discussion
We describe a distmct phenotype assodated with five dif-
ferent NF1 missense mutations (p.Argl809Cys, p.Argl809Leu,
p.Argl809Pro, p.Argl809Ser, and p.Argl809Gly) in a large cohort
of 136 mdividuals. Missense mutations affecting NF1 p.Argl809
were found in 1.23% ofunrelated NF1 mutation-positive individ-
uals in the UAB cohort, therefore the current findings wiU impact
management and counseling of a large number of famüies.
p.Argl809CYS is the most recurrent missense mutation in the
NF1 gene, found m 68/7,000 (0.97%) unrelated mutarion-positive
individuals mthe UAB cohort. This variant was mitiaüymisclassified
as a rare polymorphic variant [Ars et al., 2003] due to finding
this variant m a sporadic individual and presence of the variant m
several "unaffected" üldividuals (mother and sibling). [Ars et al.,
2003] acknowledged that for some families the clinical information
in their cohort was ümited. Nyström et al. (2009) was hesitant
how to classify p.Argl809Cys m a famfly consistmg of a proband
with severe Noonan syndrome with a de novo PTPN11 as weU as
inherited NF1 p.Argl809Cys missense mutation and four relatives
with multiple CALMs: 2 carrying (sibling and father) and two not
carrying (patemalunde and cousin) NF1 p.Argl809Cys. As detailed
examination of the CALMs in the paternal uncle and cousül was
not possible, a different genetic disorder in this branch of the famüy
cannot be excluded. As other loei for famiüal CALMs remain to be
discovered [Messiaen et al., 2009], whole exome sequencmg may
shed light on the genetic make-up in dus and other families. In
addition, several other families have been reported where mutations
in more than one gene, involved in disorders with an overlapping
phenotype, segregated withm a family [Bertola et al., 2005; Messiaen
et al., 2009; this study]. Understanding of the phenotypic spectrum
associated with NF1 mutations has expanded significantly with the
increased use ofNFl genetic testing and the identification fpatients
with a specific mutadon such as p.992delMet, who-amongst o her
features-do not develop the typical neurofibromas with age and
not all ftiUiü NIH criteria even in late adulthood [Upadhyaya et al.,
2007]. Furthermore, guideUnes and recommendations have been
estabUshed and refined to help with the standardized assification
of genetic variants [Richards et al., 2008; Richards et al., 2015].
Novel NF1 missense variants rarely can be cönfidendy classified
based on observations in a single proband/famüy and often remam
a "variant ofunknown sigmficance" until more evidence becomes
avaüable. Based on the evaluation of >100 unrelated famüies and
one segmental NP individual (this study, [Nyström et al., 2009;
Ekvall et al., 2014; Pimia et al., 2015; Santoro et al., 2015]) sufficient
evidence is avaüable to classify all five missense mutations presented
here as pathogenic. The famüy originally included in the study by
[Ars et al., 2003] was dmically re-evaluated in dus study (BARC-
123) and the clmical phenotype was found to be concordant with
the distinct phenotype described here. Nevertheless, fürther studies
in large Argl809-missense mutation positive famüies wül refine
our understanding of the phenotypic variability withm families and
aUow detenninmg whether non-peneüance ould exist at this locus,
as suggested by the presence of three mdividuals with only 1-2
CALMs in our cohort (UAB-R008-I1, UAB-R5863-I1, and UAB-
R6673-I1; it remains unknown if these individuak were founders,
and therefore might have been mosaic).
p.Argl809 is located at the end of the C-terminal o'-helix:, dose
to the end of the PH-like domain which forms a bipartite module
with the Sec-14 domain. 3D-modeling predicts a loss of a hydro-
gen bond between p.Serl738 in both the solvent and lipid bound
model for aU six missense variants that can arise after a substitution
of the Argl809 CGC codon, suggesting this may cause a change
in the secondary structure of the PH-Uke domain with possible
effect on domain interacüon and lipid-bmding properties of the
adjacent Sec-14 domain. However, other domains involving, for ex-
ample, the amino acids 1817-2818, whose crystal structures remain
unresolved, may affect he stabüity and structure of this domam,
therefore the predicted loss of the hydrogen bond with p.Serl738
mayormaynotbe crucial. p.Argl809His, expectedtobe quaUyfïe-
quent as p.Argl809Cys, given the equal likeBhood for both variants
to originate as a coMequence of deammation after methylation of
the CpG dinucleotide of the CGC codon, has never been observed
as a constitutional mutation in patients or in 61486 ExAC control
samples. On the other hand, p.Argl809His is present as a somatic
mutation m the COSMIC database in large mtestine carcmomas
(1/131 vs. 2/131 for p.Argl809Cys), which does however not imply
pathogenicity asp-Argl 809His could just be a passenger subsequent
spontaneous deammation at this site. Interestingly, Arg is evolution-
ary conserved own to yeast IRA2 whereas Lys is present at this site
in IRA1. As Arg, His, and Lys aU share a simüar basic side chain, we
postulate this charge at position 1809 is important for normal fünc-
tion which may explain why p.Argl 809His has not been observed in
patients o far. We therefore hypothesize that p.Argl809His is either
not pathogenic or results m a different phenotype.
The present data mdicate that p.Argl809 missense mutations are
associated with a distinct NF1 phenotype of multiple CALM, with
or without skinfold freckling and Lisch nodules, but a significandy
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reduced fi-equency of NFl-assodated benign and malignant u-
mors. Multiple (>5) CALMs are usuaUy the first sign mdicative
of NFl and present shorüy after birth. Up to 90% of the pa-
tients thereafter develop skmfold freckUng before the age of 8
years, thereby fülfillüig the clinical criteria ofNFl [Friedman et al.,
19S6a]. Typicaüy, more signs and complications develop thereafter,
but few indicators predict he severity of the disorder over urne.
This uncertamty negatively impacts quaüty ofüfe [Vranceanu et al.,
2013].
The most striking fmdmg is the paudty of cutaneous, subder-
mal and extemallyvisible plexiform neurofibromas. Cutaneous and
subcutaneous neurofibromas re benign tumors that start growing
during puberty. Typically, adult patients have multiple to thousands
ofthem. As they cause esthetic and social disabüitywith a significant
effect on the quaUty oflife in post-pubertal mdividuals, the current
findings are important for a large group ofpatients.
In addition, summarizing all available evidence so far, no exter-
naUy visible plexiform neurofibromas were found m 107 individuals
olderthan 9 years [Nyström et al., 2009; this study; Ekvall et al., 2014;
Pinna et al., 2015; Santoro et al., 2015]. Plexiform neurofibromas are
prone to undergo malignant transformation, with an NF1 patient's
lifetime risk ofdeveloping a MPNST estimated at 5.9%-13% [Evans
et al-, 2002; McCaughan et al., 2007]. Importanüy, no MPNSTs were
observed m 59 mdividuals between 19 and 87 years ofage [Nyström
et al., 2009; Ekvall et al., 2014; Pinna et al., 2015; Santoro et al"
2015]. Caution remains needed however, as minor lesions might be
missed on a routine clinical exammation. Moreover, full body imag-
ing would be needed to exclude the presence ofinternal peripheral
nerve sheath tumors.
NF1 -related optie gliomas occur m 15%-20% ofchfldren and are
most often asymptomatic [Listernick et al., 2007]. Although routme
MRI is not indicated in an asymptomatic duld, visual assessment is
recommended as standard of care m NF1 patients, even in younger
chUdren, to detect decreased visual acuity and proptosis, the most
common symptoms caused by optie glioma requiring MRI. The
mean age of diagnosis of a symptomatic optie gUoma is 5 years
[Nicolin et al., 2009]. No symptomatic opüc pathway glioma (0/153,
with 114/153 2:5 years), includüig no optie pathway glioma by MRI
in au 42 mdividuals >5 years was found (this study and [Pinna
et al., 2015]). A brain lesion was present m four mdividuals in our
study, including one paüent where the physician decided to treat
(right halamic, histologically confirmed astrocytoma treated with
stereotactic radiosurgery and chemotherapy at the age of 17 years,
due to changes in the tumor perceived on imaging prior to NF1
genetic testing). Collection of greater datasets is needed to further
refine the decreased tumor risk associated with Aigl809 missense
mutations.
No systematic occurrence of any other tumor, except lipomas
(10/136 individuals, this study and [Nyström et al., 2009] has
been associated with missense mutations at p.Argl809. Absence
of a clear tumor phenotype may indicate that Argl809 acts düïer-
endy compared to truncating NF1 mutations and may be a hypo-
morphic, gam-of-fünction rdominant-negative acting mutation.
However, p.Argl809Cys behaves as a loss-of-function mutation in
melanocytes trom CALMs as evidenced by the identification of 2
mutations ia the patiënt with segmental NF1 presentation, UAE-
RSeNF23, in line with our previous finding of NF1 actmg as a
tumor suppressor in these cells [Maertens et al" 2007; De Schepper
et al., 2008].This finding questions but does not exclude for other
tissues the often raised suspicion that NF1 missense mutations as-
sociated with aNF-Noonan phenotype may exert a gam offünction
or dommant-negative ffect. Additional functional studies would
be needed to shed further light on this.
A co-occurrence of p.Argl809 and vascular abnomialities was
observed, of interest given the baown association between RASA1
(p. 120-RASGAP; MIM #139150), another guanosine triphosphatase
activating protein with simüar RAS-MAPK-downregulatmg func-
tion as neurofibromm, and abnormal angiogenesis [Revencu et al"
2008].
Three individuals with the p.Argl809Cys mutation in this cohort
and l patiënt with both the p.Argl 809Cys and PTPNl l p.Phe285Leu
mutations [Nyström et al" 2009] presented with an Arnold-Chiari
type l malformaüon. Whüe Arnold Chiari type l malformarion has
been more frequenfly reported in PTPN11, its association with NF1
is stiü under discussion [Plümpe N et al., 2010]. The true incidence
of this malformation isonly recendy being understood with the
mcreased use ofMRI, and the prevalence in the general population
may be as high as 1/1280 according to recent estimates [Meadows
et al., 2000; Boyles et al., 2006]. Therefore, the data presented here
may suggest a possible association between Amold-Chiari l malfor-
mation and the NF1 p.Argl809Cys mutation.
Pectus abnormalities (pectus excavatum, pectus carinatum) were
significandy less frequent in the Argl809-missense mutation-
positive mdividuals compared to classic NF1 (P < 0.0001).
Learnmg disabilities, cognitive ünpairment and abnormal devel-
opment were frequently reported in this cohort, especially speech
and language delays, AD(H)D, gross and fine motor delays. Signif-
icant learning disabüities or intellectual disabflity were reported m
S individuals. As the learning disabüities remain a significant con-
cern in this group ofpatients, we propose to refer to the assodated
phenotype as being distinct, rather than mild.
As patients referred for genetic testing were commg from many
different clmics, it was not possible to obtain standardized ata on
the extent of the learning disabiüties. Therefore, further studies are
needed to systematicaUy investigate problems with speech, language,
learaing, and behavior in Argl809-missense mutation-positive m-
dividuals.
Features/complications belonging to the Noonan-spectrum were
present in significaiit excess (26.2%). Perceptkm offacial and dys-
morphic features is however somewhat subjective, whereas hort
stature and PS are objective findings. Although more than 80% of
NF1 patients have an average height below expected for age, only
5%-7% have true short stature (height more than 3 standard evia-
tionsbelow average) [Friedmanetal., 1986b].Thecohortsdescribed
by Huson et al. (1988) and Khosrotehrani et al. (2005) report short
stature in a higher percentage ofindividuals (15.9%) and therefore,
we used the latter frequency, conservatively, for our comparisons.
Quantitative data on height for age were evaluated rigorously in this
study, taking ethnic background into consideration and only con-
sidermg short stature when height was :£PC3. Short stature (:SPC3)
was present in 35.4%, highly significanüy more prevalent than in
classic NF1 (P < 0.0001).
PS was also present m excess in p.Argl809-missense mutation-
positive individuals compared with the dassic NF1 cohorts. The
current finding supports that PS m NF1 might be more frequently
found in paüents carrying a non-truncating mutation [Ben-Shachar
et al., 2013], although none of the previous tudies had identified
this recurrent p.Argl809 missense mutadon in their cohort. The as-
sociation ofArgl 809 with short stature and PS remamed undetected
in the study by Püuia et al., 2015 (short stature in 1/10 individuals
and PS in 0/10) and Santoro et al., 2015 (short stature in 0/15 and
PS in 0/13). However, the power to detect differences m the fre-
quency ofspecific complications in this cohort versus classic NF1,
with a significance at the 5% level, is lower in a cohort of 23 and 25
individuals: power of 69% to detect he increased frequency of PS
(12.5% m this cohort vs. 1.1% in classic NF1) and power of 60% to
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detect he increased frequency of short stature (35% in this cohort
vs. 15.9% in classic NF1).
Cohorts of individuals with the NF1 mutations at p.Argl809,
p.Met992del, and LS share the low frequency of benign and
maügnant umors. Based on our epidemiological data, 86/7,000
mutation-positive unrelated individuals cairy a gennline mutation
atp.Argl809 and 55/7,000 atp.Met992del (Messiaen, unpubUshed).
In addition, as ~2% of individuals fulfiILmg NIH criteria have LS
(Messiaen et al., 2009) and, as only ~38% ofreported cases with LS
fulfill NIH criteria by the age of 9 years, alarger group ofmdividu-
als with CALMs with or without skmfold frecklmg exist for whom
identification of the aforementioned genetic hanges may relieve
the psychosocial burden and anxiety associated with uncertamty
and wairing for tumor symptoms to develop.
Considering complicaüons that can be found in the general pop-
ulation with a frequency of ~ 1/1,000 (e.g., phaeochromocytoma,
Arnold-Chiari type l malformation, etc.), combining data from
this (n = 39) and previous studies (n = 21) on 60 Argl809-missense
mutation-positive adults (>. 19 year) results in a power esümate of
more than 85% to detect compUcations as being associated with
this mutation and occurring in at least 5% ofArgl809-positive m-
dividuals.Combiningdatafromthis (n= 111) and previous studies
(n = 33) on 143 Argl809-positive individuals aged S.5 years, we
estimated in post-hoc power calculation that his sample size would
aUow detection of compücations with a prevalence of at least 3%
with a power of 92%, and of at least 2% with a power of 75%.
CompUcations that are even rarer would require larger cohorts to
show up as being associated with this mutation. This caUs for care-
fid coUection of additional genotype and phenotype data as 250
weü-characterized, preferably adult padents are needed to identify
complications present wiüi a frequency of only Wo. We therefore
call for an international effort o collect accurate phenotypic data
on these patients.
A limitation of the current study is the heterogeneity of the dini-
cal data, with many climcal NF experts involved, although the same
standardized questionnaire was used to collect he data. Data were
interrogated extensively, first hrough the initial submission of the
questioimaire as part of the cünical testing, followed by a request
to confirm and update the data and to clarify unclear data. This
approach may result in over-reportmg of certain signs and symp-
toms compared to classic cohorts ofaggregated data that were only
mterrogated once.
Therefore, for those symptoms that are statistically significantly
less frequent in the Argl809-missense positive cohort, the findmgs
are even more significant as information was coUected and veri-
fied twice: therefore we do not anticipate underreportmg for these
spedfic features in our cohort.
On the other hand, we have features that are cleariy more frequent
in the Argl809-missense positive cohort compared with classic NF1
cohorts, especially short stature (35.4%; P< 0.0001) and PS (12.5%;
P < 0.0001). As length for a given age is expressed as a discrete
quantitative measurement there cannot be bias in the resultmg data.
Also, the excess ofPS in mdividuals carrying an Argl809-missense
mutation cannot be attributed to ascertaüunent bias. It is standard
of care for children to be evaluated with echocardiograms ifa heart
murmur is present or suspected. Moreover, the difference in PS
frequency between the Argl809 cohort and the classic NF1 cohorts
(12.5% vs. 1.1%) isverylarge.
Missense mutations afFectmg p.Argl809 are the second most fre-
quent mutation m the UAB cohort, second only to the 1.4 Mb NF1
type l microdeletion. Therefore, the current findings affect a large
number of individuals. Finding this genotype m an mdividual or
family will impact counseling and management, thus providmg an
incentive to perfonn constitutional NF1 mutation analysis. More-
over, if a substantial deviation from the here described phenotype
is found m an inferred (i.e., a relative ofan individual with aproven
p.Argl809 missense mutation) as weu as m a proven p.Argl809
missense mutation carrier, further genetic investigations hould be
pursued. Communicatmg this information to the patients mcludmg
the necessary nuances and detail is best done by genetic ounselors
and climcians pecialized in the complexity ofNFl. It is important
that clinidans mvolved in the care ofpatients with NF1 are aware
of these emerging genotype-phenotype correlations that may alter
surveillance and management.
The current data demonstrate hat genotype-phenotype correla-
tions in NF1 exist and may be relevant to management and surveil-
lance of these paüents. Therefore a renewed mterest in these studies
and close coUaboration between NF1 clinicians and molecular ge-
neticists are needed to come to a timely unfoldmg ofadditional such
con-elations.
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